相关实验视频
Updated: Feb 27, 2026

05:37
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
2.7K
如何根据政策建模一致性 (PMC) 指数模型评估罕见病政策的有效性:对中国政策实施的定量评估
Yue Zhao1, Xinyu Zhang2, Da He3
1Shanghai Institute for Science of Science, Shanghai, China.
Intractable & rare diseases research
|February 26, 2026
概括
中国的罕见病政策显示出一个完善的结构,具有"优秀可接受"的政策建模一致性 (PMC) 指数. 然而,对于罕见疾病患者的激励和社会支持系统需要改进.
科学领域:
- 卫生政策 卫生政策
- 公共卫生 公共卫生
- 社会政策 社会政策 社会政策
背景情况:
- 中国的罕见病政策体系需要进行系统的评估,以了解其结构特征和一致性.
- 评估国家和区域政策对于确定罕见疾病治理的优势和弱点至关重要.
研究的目的:
- 通过政策建模一致性 (PMC) 指数,系统地评估中国的国家和地区的罕见病政策.
- 揭示2016年至2025年中国罕见病政策体系的结构特征,一致性水平和主题演变.
主要方法:
- 利用政策建模一致性 (PMC) 指数模型来评估19个国家和13个区域的罕见病政策文件.
- 采用ROSTCM 6.0软件用于高频关键字提取和语义网络分析以确定政策重点.
- 构建了一个PMC评估系统,用于对政策文件进行定量和视觉分析.
主要成果:
- 中国罕见病政策的平均PMC指数为5.31 (国家) 和4.94 (地方),表明整体"优秀可接受"范围.
- 在政策性质,功能和结果导向方面观察到更高的分数,反映出强有力的战略规划.
- 在激励措施,患者支持和社会支持方面得分较低,突出显示需要改进的领域.
结论:
- 中国的罕见病政策体系在结构上发达,国家政策侧重于顶级设计,地方政策侧重于创新.
- 加强激励和社会支持系统,促进协调立法,建立国家信息平台对于优化至关重要.
- 建议建立一个全面的政策链,以加强罕见病政策框架.
相关概念视频
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
Methods of Documentation VI: Case Management Model
980
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
980
Pharmacokinetic Models: Comparison and Selection Criterion
424
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
424
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Analysis of Population Pharmacokinetic Data
854
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
854
Pharmacodynamic Models: Linear Concentration–Effect Model
32
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
32

